EGFR and neoplasm: Preclinical studies demonstrated that ABY-029 dosing 4 to 8 h before tumor dissection optimizes tumor-to-background contrast34 and facilitates same-day tracer dosing, a favorable development compared with conventional EGFR-targeted antibody-based tracers that require infusion multiple days before surgery.